Medications

FDA panel narrowly sides against experimental ALS drug

Federal health advisers on Wednesday narrowly ruled against an experimental drug for the debilitating illness known as Lou Gehrig's disease, a potential setback for patient groups who have lobbied for the medication's approval.

Medications

FDA reviewers give thumbs down to new ALS drug

Despite months of intense lobbying by patient advocates, federal health officials on Monday posted a largely negative review of an experimental drug for amyotrophic lateral sclerosis (ALS).

page 10 from 40